Form 4: Arcellx Director, Kavita Patel, Executes Stock Option and Sells Shares Under 10b5-1 Plan

Arcellx director Kavita Patel exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan on December 3, 2024.

Summary

• Kavita Patel, a director at Arcellx, Inc., executed a stock option to acquire 1,500 shares of common stock at a price of $6.66 per share on December 3, 2024.
• On the same day, Ms. Patel sold a total of 1,500 shares of Arcellx common stock in multiple transactions at prices ranging from $88.34 to $96.24 per share.
• These sales were conducted under a pre-arranged Rule 10b5-1 trading plan established on March 28, 2024.
• The transactions resulted in a net change in Ms. Patel's holdings of Arcellx common stock, with the sale of 1,500 shares offsetting the acquisition of 1,500 shares through the option exercise.

Sentiment

Score: 5

Explanation: The document reflects routine insider transactions under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which is common for publicly traded companies. The use of a 10b5-1 trading plan is a standard practice for corporate insiders to avoid accusations of trading on non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives and directors at publicly traded companies, including those in the biotechnology sector like Arcellx.
• Similar filings are regularly made by insiders at companies like Gilead Sciences, Amgen, and Regeneron, reflecting routine stock transactions.
• The vesting schedule of the stock options is also typical, with a portion vesting after one year and the remainder vesting monthly thereafter, which is a standard practice in equity compensation plans.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are routine insider sales under a pre-arranged plan.
• The sales do not indicate any change in the company's fundamentals or future prospects.

Key Dates

Keywords

Arcellx, stock options, insider trading, Form 4, Rule 10b5-1, Kavita Patel, equity incentive plan, share sales, director